SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-18-000151
Filing Date
2018-01-05
Accepted
2018-01-05 17:05:04
Documents
4
Period of Report
2017-12-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT azrx8k_dec312017.htm 8-K 39015
2 FORM OF EXERCISE LETTER ex10-1.htm EX-10.1 36378
3 FORM OF PARTIAL EXERCISE LETTER ex10-2.htm EX-10.2 45588
4 IMAGE azrxlogo.jpg GRAPHIC 8115
  Complete submission text file 0001654954-18-000151.txt   133561
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 18514102
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1